Both CCD and CYCLOPS were highly successful at showing, for the first time, that circadian rhythms are disrupted in patient tumors and not just preclinical cell line and mouse models; however, given that both of these methods are at the population level and require large cohorts of patients to execute, in their current forms they are not a viable way to assess the state of the clock in individual patient tumor biopsies [18,172]. The gene discussed is CLOCK; the disease is neoplasm.